From a therapeutic perspective, FSP1 appears to be a better therapeutic target than GPX4 in cancer treatment, as inhibiting FSP1 presumably would cause less toxicities in normal tissues than would inhibiting GPX4. Here, AIFM2 is linked to cancer.